David is an entrepreneur with more than 20 years of international experience in research, product development, management & business development in the field of life sciences. He has a great interest in solving some of the biggest problems in human health and has led companies seeking to provide game-changing cures in cancer, Alzheimer’s, Parkinson’s and other neurodegenerative diseases. David strongly believes in deploying multidimensional approaches to tackle big problems, and in utilizing data mining and bioinformatics, molecular biology and innovative drug discovery and clinical development approaches. David is a leader, entrepreneur, outside-the-box strategic thinker, multitasker, team player, persistent, and high-energy individual.
David was founder & CEO of LifeMap Sciences, Inc.; founder & CEO of XenneX, Inc.; and founder & CEO of Avraham Pharmaceuticals, Ltd.; and founder of Varinel, Inc.; VP, Business Development at Paramount Biosciences; and Director of Business Development World Wide at Compugen Inc. From 1996-1999 he was a research fellow at Harvard and Harvard Medical School. He earned his Ph.D. in Molecular Biology in 1995 from the University of Illinois at Chicago and B.Sc. in Biology from Tel Aviv University in 1991.
Rick brings a broad understanding of pharmaceutical industry based upon 30 years of experience in research and development functions. Rick brings a proven ability to resolve issues, lead teams and deliver outcomes in compliance with government and industry regulations.
Rick's experience includes a balanced portfolio of critical pharmaceutical development skills and experiences developed within multiple environments, including Avraham Pharmaceuticals, Ltd., YM Biosciences, Inc., Eximias Pharmaceuticals, Corp., and New River Pharmaceuticals, Inc., Fifteen years in various research, regulatory and project management positions at AstraZeneca Pharmaceuticals, and 8 years as staff scientist at E.I. Du Pont de Nemours & Co. Rick earned his M.S. in Biochemistry, University of Kansas, Lawrence, KS, 1981 and his B.Sc. in Neuropsychology, University of Virginia, Charlottesville, VA, 1975.
Bob brings broad experience in novel therapeutic approaches to prevention and treatment of metastasis, biomarkers for diagnosis and prognosis of malignancy and the carcinogenic process. Bob is Professor Emeritus, Department of Urology, University of Oklahoma Health Sciences Center. He was also a founder of DormaTarg.
Bob has published over 150 peer reviewed papers and is listed as an inventor on 11 patents to date. In 2009 he was named "Innovator of the Year" by the "Oklahoma Journal Record", the State's business newspaper. Bob is a Fellow of the American Association for the Advancement of Science. Bob earned his Bachelor's of Science from Auburn University and his Ph.D. in biochemistry from Florida State University.
Raphael is a scientist, entrepreneur and angel investor with 27 years of biotechnology experience spanning preclinical research, drug discovery, cell-based assays, process development and recombinant cytokines production. He is founder and owner of SBH Sciences, which he built from the ground up to become a leading supplier of recombinant cytokines and a preferred discovery research organization that has assisted more than 180 biotechnology companies since 1997.
Raphael also co-founded the biotechnology companies Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics, is co-founder of SBH Diagnostics, and co-founder and partner at Sky Ventures, Woodland Biosciences and ABI-LAB. Raphael earned his Ph.D. in biotechnology his M.S. in biochemistry, and his B.S. in chemistry from Tel-Aviv University and his M.S. in engineering management from New Jersey Institute of Technology. He was a postdoctoral researcher at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production.
Copyright © 2017 Vuja De Sciences lnc. - All Rights Reserved.